Skip to main content

Advertisement

SpringerLink
Log in

Targeted therapies in gastric cancer treatment: where we are and where we are going

  • REVIEW
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Gastric cancer (GC) is one of the most common malignancies and a major cause of cancer-related deaths worldwide. Its incidence has significantly declined over the last few decades, probably due to the identification of specific etiologic agents such as Helicobacter pylori and other dietary and environmental risk factors. Nevertheless, most of the cases are unfortunately diagnosed at an advanced stage justifying median overall survival rates frequently not exceeding one year. Palliative combination chemotherapy usually represented by a platinum-based doublet is the mainstay of treatment in the metastatic setting. Adding a third drug such as an anthracycline or a taxane has been shown to improve response rate and provide limited survival benefits in fit selected patients. Unlike other tumors, the introduction of molecularly targeted drugs in the medical armamentarium for GC is relatively recent with trastuzumab and ultimately ramucirumab constituting the only agents approved to date. Recent advances in the understanding of GC biology have led to the development of novel targeted therapies holding the promise to further improve treatment outcomes. The aim of this paper is to review the main available data coming from clinical trials of targeted drugs and to describe some of the most interesting molecules in clinical development in GC. These include drugs targeting EGFR, angiogenesis, c-MET, FGFR2, mTOR and immune checkpoints.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2012) Global cancer statistics. CA Cancer J Clin 65:87–108. doi:10.3322/caac.21262

    Article  Google Scholar 

  2. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin 62:10–29. doi:10.3322/caac.20138

    Article  PubMed  Google Scholar 

  3. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903

    Article  CAS  PubMed  Google Scholar 

  4. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE (2010) Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. doi:10.1002/14651858.CD004064.pub3

    PubMed  Google Scholar 

  5. Van Cutsem E, VM M, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, ML R, JA A, V325 Study Group (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991–4997

    Article  PubMed  CAS  Google Scholar 

  6. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK, Investigators TGAT (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687. doi:10.1016/S0140-6736(10)61121

    Article  CAS  PubMed  Google Scholar 

  7. Kasper S, Schuler M (2014) Targeted therapies in gastroesophageal cancer. Eur J Cancer 50:1247–1258. doi:10.1016/j.ejca.2014.01.009

    Article  CAS  PubMed  Google Scholar 

  8. Holbro T, Civenni G, Hynes NE (2003) The ErbB receptors and their role in cancer progression. Exp Cell Res 284:99–110

    Article  CAS  PubMed  Google Scholar 

  9. Kim KC, Koh YW, Chang HM, Kim TH, Yook JH, Kim BS, Jang SJ, Park YS (2011) Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol 18:2833–2840. doi:10.1245/s10434-011-1695-2

    Article  PubMed  Google Scholar 

  10. Barros-Silva JD, Leitão D, Afonso L, Vieira J, Dinis-Ribeiro M, Fragoso M, Bento MJ, Santos L, Ferreira P, Rêgo S, Brandão C, Carneiro F, Lopes C, Schmitt F, Teixeira MR (2009) Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer 100:487–493. doi:10.1038/sj.bjc.6604885

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Takehana T, Kunitomo K, Kono K, Kitahara F, Iizuka H, Matsumoto Y, Fujino MA, Ooi A (2002) Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 98:833–837

    Article  CAS  PubMed  Google Scholar 

  12. National Cancer Institute. FDA approval for trastuzumab. Available from http://www.cancer.gov/about-cancer/treatment/drugs/fda-trastuzumab

  13. Okines AF, Cunningham D (2012) Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer. Ther Adv Gastroenterol 5:301–318. doi:10.1177/1756283X12450246

    Article  Google Scholar 

  14. Ryu MH, Yoo C, Kim JG, Ryoo BY, Park YS, Park SR, Han HS, Chung IJ, Song EK, Lee KH, Kang SY, Kang YK (2015) Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. Eur J Cancer 51:482–488. doi:10.1016/j.ejca.2014.12.015

    Article  CAS  PubMed  Google Scholar 

  15. Kurokawa Y, Sugimoto N, Miwa H, Tsuda M, Nishina S, Okuda H, Imamura H, Gamoh M, Sakai D, Shimokawa T, Komatsu Y, Doki Y, Tsujinaka T, Furukawa H (2014) Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). Br J Cancer 110:1163–1168. doi:10.1038/bjc.2014.18

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Mitsui Y, Sato Y, Miyamoto H, Fujino Y, Takaoka T, MiYoshi J, Kagawa M, Ohnuma H, Hirakawa M, Kubo T, Osuga T, Sagawa T, Sato Y, Takahashi Y, Katsuki S, Okuda T, Takimoto R, Kobune M, Nobuoka T, Hirata K, Kato J, Takayama T (2015) Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2- positive metastatic gastric cancer: feasibility and preliminary efficacy. Cancer Chemother Pharmacol 76:375–382. doi:10.1007/s00280-015-2807-7

    Article  CAS  PubMed  Google Scholar 

  17. NCT01295086: Dose determination of Taxotere, Eloxatin and Xeloda (TEX) in combination with Herceptin in patients with HER2 positive non-resectable oesophagus, cardia or gastric cancer. Available from www.clinicaltrials.gov

  18. NCT01450696: HELOISE study: a study of Herceptin (Trastuzumab) in combination with Cisplatin/Capecitabine chemotherapy in patients with HER2-positive metastatic gastric or gastro-esophageal junction cancer. Available from www.clinicaltrials.gov

  19. Hofheinz R, Hegewisch-Becker S, Thuss-Patience PC, Kunzmann V, Fuchs M, Graeven U, Homann N, Heinemann V, Pohl M, Tannapfel A, Al-Batran S (2014) HER-FLOT: Trastuzumab in combination with FLOT as perioperative treatment for patients with HER2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the AIO Gastric Cancer Study Group. J Clin Oncol 32:5s

    Article  CAS  Google Scholar 

  20. Barok M, Joensuu H, Isola J (2014) Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res 16:209. doi:10.1186/bcr3621

    Article  PubMed  PubMed Central  Google Scholar 

  21. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K (2012) EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783–1791. doi:10.1056/NEJMoa1209124

    Article  CAS  PubMed  Google Scholar 

  22. NCT01641939: A Randomized, multicenter, adaptive phase II/III study to evaluate the efficacy and safety of Trastuzumab Emtansine (T-DM1) versus taxane (Docetaxel Or Paclitaxel) in patients with previously treated locally advanced or metastatic Her2-positive gastric cancer, including adenocarcinoma of the gastroesophageal junction. Available from www.clinicaltrials.gov

  23. Metzger-Filho O, Winer EP, Krop I (2013) Pertuzumab: optimizing HER2 blockade. Clin Cancer Res 19:5552–5556. doi:10.1158/1078-0432.CCR-13-0518

    Article  CAS  PubMed  Google Scholar 

  24. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J, CLEOPATRA Study Group (2015) Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. N Engl J Med 372:724–734. doi:10.1056/NEJMoa1413513

    Article  CAS  PubMed  Google Scholar 

  25. Hoff P, Tabernero J, Shen L, Ohtsu A, Yu R, Szado T, Kang YK (2013) Pertuzumab, Trastuzumab anch chemotherapy in HER2-positive metastatic gastric or gastro-oesophageal junction cancer: an international phase III study (JACOB). Ann Oncol 24(suppl 4):iv67

    Article  Google Scholar 

  26. Untch M, Lück HJ (2010) Lapatinib - Member of a New Generation of ErbB-Targeting Drugs. Breast Care 5:8–12

    Article  PubMed  PubMed Central  Google Scholar 

  27. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743

    Article  CAS  PubMed  Google Scholar 

  28. Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J (2012) Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 30:2585–2592. doi:10.1200/JCO.2011.35.6725

    Article  CAS  PubMed  Google Scholar 

  29. Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538–5546. doi:10.1200/JCO.2009.23.3734

    Article  CAS  PubMed  Google Scholar 

  30. Hecht JR, Bang YJ, Qin S, Chung HC, Xu JM, Park JO, Jeziorski K, Shparyk Y, Hoff PM, Sobrero AF, Salman P, Li J, Protsenko S, Buyse ME, Afenjar K, Kaneko T, Kemner A, Santillana S, Press MF, Slamon DJ (2013) Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial. J Clin Oncol 31(suppl.):abstr LBA4001

    Google Scholar 

  31. Satoh T, Xu RH, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A, Bang YJ (2014) Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN–a randomized, phase III study. J Clin Oncol 32:2039–2049. doi:10.1200/JCO.2013.53.6136

    Article  CAS  PubMed  Google Scholar 

  32. Kumar A, Petri ET, Halmos B, Boggon TJ (2008) Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 26:1742–1751. doi:10.1200/JCO.2007.12.1178

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Wang KL, Wu TT, Choi IS, Wang H, Resetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Albarracin CT (2007) Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 109:658–667

    Article  CAS  PubMed  Google Scholar 

  34. Galizia G, Lieto E, Orditura M, et al. (2007) Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg 31:1458–1468

    Article  PubMed  Google Scholar 

  35. Atmaca A, Werner D, Pauligk C, Steinmetz K, Wirtz R, Altmannsberger HM, Jäger E, Al-Batran SE (2012) The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer. BMC Cancer 12:524. doi:10.1186/1471-2407-12-524

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Martinelli E, De Palma R, Orditura M, De Vita F, Ciardiello F (2009) Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 158:1–9. doi:10.1111/j.1365-2249.2009.03992.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. National Cancer Institute. FDA approval for cetuximab. Available from http://www.cancer.gov/about-cancer/treatment/drugs/fda-cetuximab

  38. Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY (2009) Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 100:298–304. doi:10.1038/sj.bjc.6604861

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Moehler M, Mueller A, Trarbach T, Lordick F, Seufferlein T, Kubicka S, Geissler M, Schwarz S, Galle PR, Kanzler S, German Arbeitsgemeinschaft Internistische Onkologie (2011) Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Ann Oncol 22:1358–1366. doi:10.1093/annonc/mdq591

    Article  CAS  PubMed  Google Scholar 

  40. Lordick F, Luber B, Lorenzen S, Hegewisch-Becker S, Folprecht G, Wöll E, Decker T, Endlicher E, Röthling N, Schuster T, Keller G, Fend F, Peschel C (2010) Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer 102:500–505. doi:10.1038/sj.bjc.6605521

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Götte H, Melezínková H, Moehler M, Arbeitsgemeinschaft Internistische Onkologie, EXPAND Investigators (2013) Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 14:490–499. doi:10.1016/S1470-2045(13)70102-5

    Article  CAS  PubMed  Google Scholar 

  42. Dubois EA, Cohen AF (2009) Panitumumab. Br J Clin Pharmacol 68:482–483. doi:10.1111/j.1365-2125.2009.03492.x

    Article  PubMed  PubMed Central  Google Scholar 

  43. Giusti RM, Shastri KA, Cohen MH, Keegan P, Pazdur R (2007) FDA Drug Approval Summary: Panitumumab (Vectibix™). Oncologist 12:577–583

    Article  CAS  PubMed  Google Scholar 

  44. Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, Ferry D, Mansoor W, Crosby T, Coxon F, Smith D, Waters J, Iveson T, Falk S, Slater S, Peckitt C, Barbachano Y (2013) Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 14:481–489. doi:10.1016/S1470-2045(13)70096-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Okines AF, Reynolds AR, Cunningham D (2011) Targeting angiogenesis in esophagogastric adenocarcinoma. Oncologist 16:844–858. doi:10.1634/theoncologist.2010-0387

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Morishita A, Gong J, Masaki T (2014) Targeting receptor tyrosine kinases in gastric cancer. World J Gastroenterol 20:4536–4545. doi:10.3748/wjg.v20.i16.4536

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Meza-Junco J, Sawyer MG (2012) Metastatic gastric cancer - focus on targeted therapies. Biologics 6:137–146. doi:10.2147/BTT.S23917

    CAS  PubMed  PubMed Central  Google Scholar 

  48. Scartozzi M, Giampieri R, Loretelli C, Bittoni A, Mandolesi A, Faloppi L, Bianconi M, Del Prete M, Andrikou K, Bearzi I, Cascinu S (2013) Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. Pharmacogenomics 14:1991–1998. doi:10.2217/pgs.13.185

    Article  CAS  PubMed  Google Scholar 

  49. Peng L, Zhan P, Zhou Y, Fang W, Zhao P, Zheng Y, Xu N (2012) Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis. Mol Biol Rep 39:9473–9484. doi:10.1007/s11033-012-1812-8

    Article  CAS  PubMed  Google Scholar 

  50. Aprile G, Ongaro E, Del Re M, Lutrino SE, Bonotto M, Ferrari L, Rihawi K, Cardellino GG, Pella N, Danesi R, Fasola G (2015) Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight. Crit Rev Oncol Hematol. doi:10.1016/j.critrevonc.2015.02.009

    PubMed  Google Scholar 

  51. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, O'Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, Schwartz GK, Kelsen DP (2006) Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24:5201–5206

    Article  CAS  PubMed  Google Scholar 

  52. El-Rayes BF, Zalupski M, Bekai-Saab T, Heilbrun LK, Hammad N, Patel B, Urba S, Shields AF, Vaishampayan U, Dawson S, Almhanna K, Smith D, Philip PA (2010) A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol 21:1999–2004. doi:10.1093/annonc/mdq065

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP (2011) Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 29:868–874. doi:10.1200/JCO.2010.32.0770

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29:3968–3976. doi:10.1200/JCO.2011.36.2236

    Article  CAS  PubMed  Google Scholar 

  55. Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming Xu J, Peng Yong W, Langer B, Delmar P, Scherer SJ, Shah MA (2012) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 30:2119–2127. doi:10.1200/JCO.2011.39.9824

    Article  PubMed  CAS  Google Scholar 

  56. Spratlin J (2011) Ramucirumab (IMC-1121B): monoclonal antibody inhibition of vascular endothelian growth factor receptor-2. Curr Oncol Rep 13:97–102. doi:10.1007/s11912-010-0149-5

    Article  CAS  PubMed  Google Scholar 

  57. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J, Trial Investigators REGARD (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophagel junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trail. Lancet 383:31–39. doi:10.1016/S0140-6736(13)61719-5

    Article  CAS  PubMed  Google Scholar 

  58. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A, Study Group RAINBOW (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224–1235. doi:10.1016/S1470-2045(14)70420-6

    Article  CAS  PubMed  Google Scholar 

  59. Yoon HH, Bendell JC, Braiteh FS, Firdaus I, Philip PA, Cohn AL, Lewis N, Anderson DM, Arrowsmith E, Schwartz JD, Xu Y, Koshiji M, Alberts SR, Wainberg ZA (2014) Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial. J Clin Oncol 32(5s suppl):abstr 4004

    Google Scholar 

  60. Tabernero J, Ohtsu A, Muro K, Van Cutsem E, Cheul Oh S, Bodoky G, Shimada Y, Hironaka S, Ajani JA, Tomasek J, Safran H, Chandrawansa K, Hsu Y, Heathman M, Khan AZ, Ni L, Melemed AS, Gao L, Ferry D, Fuchs CS (2015) Exposure-response (E-R) relationship of ramucirumab (RAM) from two global, randomized, double-blind, phase 3 studies of patients (Pts) with advanced second-line gastric cancer. J Clin Oncol 33(suppl 3):abstr 121

    Google Scholar 

  61. NCT02314117: Randomized phase 2 trial evaluating alternative Ramucirumab doses in combination with Paclitaxel in second-line metastatic or locally advanced, unresectable gastric or gastroesophageal junction adenocarcinoma. Available from: www.clinicaltrials.gov

  62. NCT02314117: A study of Ramucirumab (LY3009806) in combination with capecitabine and cisplatin in participants with stomach cancer (RAINFALL). Available from: www.clinicaltrials.gov

  63. Liu L, Zeng W, Wortinger MA, Yan SB, Cornwell P, Peek VL, Stephens JR, Tetreault JW, Xia J, Manro JR, Credille KM, Ballard DW, Brown-Augsburger P, Wachceck V, Chow CK, Huang L, Wang Y, Denning I, Davies J, Tang Y, Vaillancourt P, Lu J (2014) Clin Cancer Res 20:6059–6070. doi:10.1158/1078-043

    Article  CAS  PubMed  Google Scholar 

  64. NCT02082210: A study of LY2875358 in combination with Ramucirumab (LY3009806) in participants with advanced cancer. Available from: www.clinicaltrials.gov

  65. Singh R, Kim WJ, Kim PH, Hong HJ (2013) Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade. Exp Mol Med 45:e52. doi:10.1038/emm.2013.111

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  66. Yamada Y, Kiyota N, Fuse N, et al. (2014) A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer. Gastric Cancer 17:161–172. doi:10.1007/s10120-013-0247-9

    Article  CAS  PubMed  Google Scholar 

  67. Kim C, Lee JL, Choi YH, Kang BW, Ryu MH, Chang HM, Kim TW, Kang YK (2012) Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Investig New Drugs 30:306–315. doi:10.1007/s10637-010-9531-2

    Article  CAS  Google Scholar 

  68. Sun W, Powell M, O'Dwyer PJ, Catalano P, Ansari RH, AB B 3rd (2010) Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 28:2947–2951. doi:10.1200/JCO.2009.27.7988

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Bang YJ, Kang YK, Kang WK, Boku N, Chung HC, Chen JS, Doi T, Sun Y, Shen L, Qin S, Ng WT, Tursi JM, Lechuga MJ, Lu DR, Ruiz-Garcia A, Sobrero A (2011) Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Investig New Drugs 29:1449–1458. doi:10.1007/s10637-010-9438-y

    Article  CAS  Google Scholar 

  70. Moehler M, Mueller A, Hartmann JT, Ebert MP, Al-Batran SE, Reimer P, Weihrauch M, Lordick F, Trarbach T, Biesterfeld S, Kabisch M, Wachtlin D, Galle PR, German Arbeitsgemeinschaft Internistische Onkologie (AIO) (2011) An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer 47:1511–1520. doi:10.1016/j.ejca.2011.04.006

    Article  CAS  PubMed  Google Scholar 

  71. Yi JH, Lee J, Lee J, Park SH, Park JO, Yim DS, Park YS, Lim HY, Kang WK (2012) Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br J Cancer 106:1469–1474. doi:10.1038/bjc.2012.100

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Fontanella C, Ongaro E, Bolzonello S, Guardascione M, Fasola G, Aprile G (2014) Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med 2:123. doi:10.3978/j.issn.2305-5839.2014.08.14

    PubMed  PubMed Central  Google Scholar 

  73. Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, Sun G, Yang Y, Wang L, Xu N, Cheng Y, Wang Z, Zheng L, Tao M, Zhu X, Ji D, Liu X, Yu H (2013) Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol 31:3219–3225. doi:10.1200/JCO.2013.48.8585

    Article  CAS  PubMed  Google Scholar 

  74. Qin S (2014) Phase III study of apatinib in advanced gastric cancer: A randomized, double-blind, placebo-controlled trial. J Clin Oncol 32(5s suppl):abstr 4003

    Google Scholar 

  75. Aprile G, Macerelli M, Giuliani F (2013) Regorafenib for gastrointestinal malignancies: from preclinical data to clinical results of a novel multi-target inhibitor. BioDrugs 27:213–224. doi:10.1007/s40259-013-0014-9

    Article  CAS  PubMed  Google Scholar 

  76. Pavlakis N et al. (2015) INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC) – a study by the Australasian Gastrointestinal Trials Group (AGITG), first results. 2015 ASCO Gastrointestinal Cancers Symposium Available from: http://meetinglibrary.asco.org

  77. NCT02406170: Regorafenib in combination with paclitaxel in advances Oesophagogastric Carcinoma (REPEAT). Available from: www.clinicaltrials.gov

  78. NCT02241720: Regorafenib second line treatment of metastatic or advanced upper GI cancer. Available from: www.clinicaltrials.gov

  79. Cidon EU, Ellis SG, Inam Y, Adeleke S, Zarif S, Geldart T (2013) Molecular targeted agents for gastric cancer: a step forward towards personalized therapy. Cancers (Basel) 5:64–91. doi:10.3390/cancers5010064

    Article  CAS  Google Scholar 

  80. Ha SY, Lee J, Kang SY, Do IG, Ahn S, Park JO, Kang WK, Choi MG, Sohn TS, Bae JM, Kim S, Kim M, Kim S, Park CK, Ignatius Ou SH, Kim KM (2013) MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Mod Pathol 26:1632–1641. doi:10.1038/modpathol.2013.108

    Article  CAS  PubMed  Google Scholar 

  81. Lee J, Seo JW, Jun HJ, Ki CS, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS, Noh JH, Kim S, Jang HL, Kim JY, Kim KM, Kang WK, Park JO (2011) Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep 25:1517–1524. doi:10.3892/or.2011.1219

    CAS  PubMed  Google Scholar 

  82. Niemann HH (2011) Structural insights into MET receptor activation. Eur J Cell Biol 90:972–981. doi:10.1016/j.ejcb.2010.11.014

    Article  CAS  PubMed  Google Scholar 

  83. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R (2002) Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 13:41–59

    Article  CAS  PubMed  Google Scholar 

  84. Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP (2013) Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One 8:e54014. doi:10.1371/journal.pone.0054014

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang YJ, Clark JW, Solomon BJ, Iafrate AJ (2011) MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 29:4803–4810. doi:10.1200/JCO.2011.35.4928

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Kang YK, Muro K, Ryu MH, Yasui H, Nishina T, Ryoo BY, Kamiya Y, Akinaga S, Boku N (2014) A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer. Investig New Drugs 32:355–361. doi:10.1007/s10637-013-0057-2

    Article  CAS  Google Scholar 

  87. Katayama R, Aoyama A, Yamori T, Qi J, Oh-hara T, Song Y, Engelman JA, Fujita N (2013) Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res 73:3087–3096. doi:10.1158/0008-5472.CAN-12-3256

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Eder P, Vande Woude GF, Boerner DS (2009) Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15:2207–2214. doi:10.1158/1078-0432.CCR-08-1306

    Article  CAS  PubMed  Google Scholar 

  89. Iveson T, Donehower RC, Davidenko I, Tjulandin S, Deptala A, Harrison M, Nirni SK, Thomas A, Jiang Y, Zhu M, Tang R, Loh E (2014) Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol 15:1007–1018. doi:10.1016/S1470-2045(14)70023-3

    Article  CAS  PubMed  Google Scholar 

  90. Cunningham D et al. (2015) Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus erubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients with advanced MET-positive gastric or gastroesophageal junction cancer: RILOMET-1 study. 2015 ASCO Annual Meeting. Available from: http://meetinglibrary.asco.org

  91. Shah H. et al. (2015) MET Gastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC). ASCO Annual Meeting Available from: http://meetinglibrary.asco.org

  92. Kwak EL, LoRusso P, Hamid O, Janku F, Kittaneh M, Catenacci DV, Chan E, Bekaii-Saab TS, Amore B, Hwang YC, Tang R, Ngarmchamnanrith G, Hong DS (2015) Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer. J Clin Oncol 33(suppl 3):abstr 1

    Google Scholar 

  93. NCT02016534: A multicenter, phase 2, single arm, two cohort study evaluating the efficacy, safety, and pharmacokinetics of AMG337 in subjects with MET amplified gastric/gastroesophageal junction/esophageal adenocarcinoma or other MET amplified solid tumors. Available from: www.clinicaltrials.gov

  94. NCT02344810: A phase I and randomized phase II double blinded placebo controlled study of mFOLFOX6 +/− AMG 337 in the first line treatment of patients with Her2/Neu negative and high MET expressing advanced gastric and esophageal adenocarcinoma. Available from: www.clinicaltrials.gov

  95. Hattori Y, Itoh H, Uchino S, Hosokawa K, Ochiai A, Ino Y, Ishii H, Sakamoto H, Yamaguchi N, Yanagihara K, Hirohashi S, Sugimura T, Terada M (1996) Immunohistochemical detection of K-sam protein in stomach cancer. Clin Cancer Res 2:1373–1381

    CAS  PubMed  Google Scholar 

  96. Takeda M, Arao T, Yokote H, Komatsu T, Yanagihara K, Sasaki H, Yamada Y, Tamura T, Fukuoka K, Kimura H, Saijo N, Nishio K (2007) AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin Cancer Res 13:3051–3057

    Article  CAS  PubMed  Google Scholar 

  97. Qiu H, Yashiro M, Zhang X, Miwa A, Hirakawa K (2011) A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells. Cancer Lett 307:47–52. doi:10.1016/j.canlet.2011.03.015

    Article  CAS  PubMed  Google Scholar 

  98. Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, Zhang S, Lee M, Wu J, Lim KH, Lei Z, Goh G, Lim QY, Tan AL, Sin Poh DY, Riahi S, Bell S, Shi MM, Linnartz R, Zhu F, Yeoh KG, Toh HC, Yong WP, Cheong HC, Rha SY, Boussioutas A, Grabsch H, Rozen S, Tan P (2012) A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61:673–684. doi:10.1136/gutjnl-2011-301839

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. NCT01921673: Dovitinib Plus Docetaxel in Gastric Cancer. Available from www.clinicaltrials.gov

  100. NCT01719549: Dovitinib for Gastric Cancer With FGFR2 Amplification. Available from www.clinicaltrials.gov

  101. NCT01457846: Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer Patients. Available from www.clinicaltrials.gov

  102. NCT01576380: A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients. Available from www.clinicaltrials.gov

  103. Lang SA, Gaumann A, Koehl GE, Seidel U, Bataille F, Klein D, Ellis LM, Bolder U, Hofstaedter F, Schlitt HJ, Geissler EK, Stoeltzing O (2007) Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 120:1803–1810

    Article  CAS  PubMed  Google Scholar 

  104. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M. (2004) PI3K/Akt signalling pathway and Cancer. Cancer Treat Rev 30:193–204.

    Article  PubMed  CAS  Google Scholar 

  105. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129:1261–1274

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Velho S, Oliveira C, Ferreira A, Ferreira AC, Suriano G, Schwartz S Jr, Duval A, Carneiro F, Machado JC, Hamelin R, Seruca R (2005) The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 41:1649–1654

    Article  CAS  PubMed  Google Scholar 

  107. Prins MJ, Verhage RJ, Ruurda JP, ten Kate FJ, van Hillegersberg R (2013) Over-expression of phosphorylated mammalian target of rapamycin is associated with poor survival in oesophageal adenocarcinoma: a tissue microarray study. J Clin Pathol 66:224–228. doi:10.1136/jclinpath-2012-201173

    Article  CAS  PubMed  Google Scholar 

  108. Xing CG, Zhu BS, Fan XQ, Liu HH, Hou X, Zhao K, Qin ZH (2009) Effects of LY294002 on the invasiveness of human gastric cancer in vivo in nude mice. World J Gastroenterol 15:5044–5052

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Mueller A, Bachmann E, Linnig M, Khillimberger K, Schimanski CC, Galle PR, Moehler M (2012) Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines. Cancer Chemother Pharmacol 69:1601–1615. doi:10.1007/s00280-012-1869-z

    Article  CAS  PubMed  Google Scholar 

  110. NCT01613950: PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer. Available from www.clinicaltrials.gov

  111. NCT01896531: A Study of GDC-0068 in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer. Available from: www.clinicaltrials.gov

  112. Doi T, Muro K, Boku N, Yamada Y, Nishina T, Takiuchi H, Komatsu Y, Hamamoto Y, Ohno N, Fujita Y, Robson M, Ohtsu A (2010) Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 28:1904–1910. doi:10.1200/JCO.2009.26.2923

    Article  CAS  PubMed  Google Scholar 

  113. Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, Sahmoud T, Shen L, Yeh KH, Chin K, Muro K, Kim YH, Ferry D, Tebbutt NC, Al-Batran SE, Smith H, Costantini C, Rizvi S, Lebwohl D, Van Cutsem E (2013) Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol 31:3935–3943. doi:10.1200/JCO.2012.48.3552

    Article  CAS  PubMed  Google Scholar 

  114. NCT01248403: A Randomized, Double-blind, Multi-center Phase III Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma Who Have Progressed After Therapy With a Fluoropyrimidine-containing Regimen. Available from www.clinicaltrials.gov

  115. Bai R, Zhao H, Zhang X, DU S. (2014) Characterization of sonic hedgehog inhibition in gastric carcinoma cells. Oncol Lett 7:1381–1384.

  116. Cohen DJ, Christos PJ, Sparano JA, Kindler HL, Catenacci DVT, Bekaii-Saab TB, Tahiri S, Janjigian YY, Gibson MK, Chan E, Rajdev L, Urba S, Wade JL, Kozuch P, Love E, Vandris K, Takebe N, Hochster HS (2013) A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led study. J Clin Oncol 31(suppl 4):abstr 67

    Google Scholar 

  117. Abdel-Rahman O (2015) Hedgehog pathway aberrations and gastric cancer; evaluation of prognostic impact and exploration of therapeutic potentials. Tumour Biol 36:1367–1374. doi:10.1007/s13277-015-3216-6

    Article  CAS  PubMed  Google Scholar 

  118. Guo YS, Beauchamp RD, Jin GF, Townsend CM Jr, Thompson JC (1993) Insulin-like growth factor-binding protein modulates the growth response to insulin-like growth factor 1 by human gastric cancer cells. Gastroenterology 104:1595–1604

    CAS  PubMed  Google Scholar 

  119. Yi HK, Hwang PH, Yang DH, Kang CW, Lee DY (2001) Expression of the insulin-like growth factors (IGFs) and the IGF-binding proteins (IGFBPs) in human gastric cancer cells. Eur J Cancer 37:2257–2263

    Article  CAS  PubMed  Google Scholar 

  120. Gryko M, Kiśluk J, Cepowicz D, Zińczuk J, Kamocki Z, Guzińska-Ustymowicz K, Pryczynicz A, Czyżewska J, Kemona A, Kędra B (2014) Expression of insulin-like growth factor receptor type 1 correlate with lymphatic metastases in human gastric cancer. Pol J Pathol 65:135–140

    Article  CAS  PubMed  Google Scholar 

  121. Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adkins D, Van Tine BA, Brockstein B, Yim V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RG (2013) Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol 14:371–382. doi:10.1016/S1470-2045(13)70049-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Cohen SJ, Feng Y, Catalano PJ, Mitchell EP, O'Dwyer PJ, Lubner SJ, Fisher GA, Mulcahy MF, Burtness B, Benson AB. (2014) E2208: Randomized phase II study of paclitaxel with or without the anti-IGF-IR antibody cixutumumab (IMC-A12) as second-line treatment for patients with metastatic esophageal or GE junction cancer. J Clin Oncol 32(5 s):abstr 4020.

  123. Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480:480–489. doi:10.1038/nature10673

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Wolchok JD, Saenger Y (2008) The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 13:2–9. doi:10.1634/theoncologist.13-S4-2

    Article  CAS  PubMed  Google Scholar 

  125. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723. doi:10.1056/NEJMoa1003466

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. NCT01585987: A Randomized, Open-label, Two-arm Phase II Trial Comparing the Efficacy of Sequential Ipilimumab Versus Best Supportive Care Following First-line Chemotherapy in Subjects With Unresectable Locally Advanced/Metastatic Gastric or Gastro-esophageal Junction Cancer. Available from www.clinicaltrials.gov

  127. Ralph C, Elkord E, Burt DJ, O'Dwyer JF, Austin EB, Stern PL, Hawkins RE, Thistlethwaite FC (2010) Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res 16:1662–1672. doi:10.1158/1078-0432.CCR-09-2870

    Article  CAS  PubMed  Google Scholar 

  128. TopalianSL HFS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454. doi:10.1056/NEJMoa1200690

    Article  CAS  Google Scholar 

  129. Sun J, Xu K, Wu C, Wang Y, Hu Y, Zhu Y, Chen Y, Shi Q, Yu G, Zhang X (2007) PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies. Tissue Antigens 69:19–27

    Article  CAS  PubMed  Google Scholar 

  130. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465. doi:10.1056/NEJMoa1200694

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  131. Muro K, Bang YJ, Shankaran V, Geva R, Catenacci DVT, Gupta S, Eder JP, Berger R, Gonzalez EJ, Ray A, Dolled-Filhart M, Emancipator K, Pathiraja K, Lunceford JK, Cheng JD, Koshiji M, Chung HC (2015) Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012. J Clin Oncol 33(suppl 3):abstr 3

    Google Scholar 

  132. NCT02335411: A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059). Available from www.clinicaltrials.gov

  133. NCT02370498: A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061). Available from www.clinicaltrials.gov

  134. NCT02267343: Phase III Study A Multicenter, Double-Blind, Randomized Study in Patients With Unresectable Advanced or Recurrent Gastric Cancer. Available from www.clinicaltrials.gov

  135. NCT01928394: A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors. Available from www.clinicaltrials.gov

Download references

Author information

Authors and Affiliations

  1. Oncology Division, Azienda Socio Sanitaria Territoriale di Cremona, Ospedale di Cremona, Viale Concordia 1, 26100, Cremona, Italy

    Gianluca Tomasello, Michele Ghidini, Wanda Liguigli, Margherita Ratti, Laura Toppo & Rodolfo Passalacqua

Authors
  1. Gianluca Tomasello
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michele Ghidini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wanda Liguigli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Margherita Ratti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Laura Toppo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rodolfo Passalacqua
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gianluca Tomasello.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tomasello, G., Ghidini, M., Liguigli, W. et al. Targeted therapies in gastric cancer treatment: where we are and where we are going. Invest New Drugs 34, 378–393 (2016). https://doi.org/10.1007/s10637-016-0330-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-016-0330-2

Keywords

Search

Navigation